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Abstract
Background Bimatoprost 0.03 % has enhanced eyelash
prominence in clinical trials enrolling mostly Caucasian
subjects. The studies described in this report evaluated the
efficacy and safety of bimatoprost in Japanese subjects with
idiopathic and chemotherapy-induced eyelash hypotrichosis.
Methods In two multicenter, double-masked, randomized,
parallel-group studies (study 1: n = 173 [idiopathic]; study
2: n = 36 [chemotherapy-induced]), subjects received bi-
matoprost 0.03 % or vehicle applied once daily to the upper
eyelid margins. The primary efficacy measure was eyelash
prominence measured by Global Eyelash Assessment
(GEA) scores. Additional measures were eyelash length,
thickness, and darkness, assessed by digital image analysis,
and patient satisfaction (Eyelash Satisfaction Questionnaire-
9). Safety assessments included adverse-event monitoring
and ophthalmic examinations.
Results Significantly more bimatoprost-treated subjects
had at least a one-grade improvement in GEA score from
baseline to month 4 compared with vehicle in study 1 (77.3
vs 17.6 %; P \ 0.001) and study 2 (88.9 vs 27.8 %;
P \ 0.001). Bimatoprost-treated subjects had significantly
greater increases in eyelash length, thickness, and darkness
at the primary time point (month 4 in both studies; all
P \ 0.001, study 1; P B 0.04, study 2). The bimatoprost
group showed greater subject satisfaction in both studies.
The incidence of adverse events was similar in the two
groups. Ophthalmic examination showed slightly greater
mean reductions in intraocular pressure (IOP) with bi-
matoprost than with vehicle, and the reductions were
within the normal range for daily IOP fluctuations.
Conclusion Bimatoprost 0.03 % was shown to be effec-
tive and safe in these studies of Japanese subjects with
eyelash hypotrichosis.
Level of Evidence I This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
Keywords Bimatoprost  Chemotherapy  Eyelashes 
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Introduction
Eyelashes are important in the concept of physical beauty,
and many women consequently use cosmetic approaches to
obtain longer and thicker lashes [1–3]. Mascara is
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frequently used to darken, thicken, and lengthen existing
eyelashes [1, 4]. In addition, a variety of over-the-counter
products containing natural extracts, vitamins, prostaglan-
din analogs, or proprietary peptides are claimed to enhance
eyelashes, but they have not been well studied, and their
effectiveness remains unproven [4].
Individuals seek eyelash enhancements for a variety of
reasons. Besides aesthetic reasons, some individuals exhi-
bit inadequate or sparse eyelashes (i.e., hypotrichosis)
characterized by reduced hair growth, which may be
attributed to known etiologies such as age, hereditary
factors, chemotherapy, and other medical treatments, but
often the etiology is unknown [5].
Individuals affected by alopecia and other associated
conditions of hair loss that might include loss of eyelashes
and eyebrows often have issues with self-identity because
they lack key facial features [6]. Hair loss, including loss of
eyelashes, is common among patients undergoing chemo-
therapy and is considered a troubling adverse effect that
can have psychosocial consequences [7, 8].
Bimatoprost 0.03 % has been developed for treating
hypotrichosis of the eyelashes. This synthetic prostaglandin
structural analog, known as a prostamide, is the same
active ingredient at the same concentration (0.03 %) found
in bimatoprost ophthalmic solution used for treatment of
open-angle glaucoma and ocular hypertension [9–11].
Eyelash growth was noted as an adverse effect of bi-
matoprost use in clinical trials of patients with glaucoma
and ocular hypertension [9, 10, 12, 13], an effect thought to
arise by the interaction of bimatoprost with prostamide-
sensitive receptors in hair follicles [14].
Bimatoprost 0.03 % solution has been shown in several
clinical trials to enhance eyelash growth when applied top-
ically to the upper eyelid margins [15–18]. On the basis of
these findings, approval of bimatoprost 0.03 % for treating
hypotrichosis of the eyelashes was granted on several con-
tinents, including North America and parts of Asia.
The studies published to date were conducted primarily
with Caucasian subjects [15, 18]. However, differences have
been observed between Asian and Caucasian individuals in
the number, thickness, and curliness of eyelashes [19].
Therefore, the two clinical trials described in this report aimed
to evaluate the efficacy and safety of bimatoprost 0.03 % for
Japanese subjects with hypotrichosis of the eyelashes.
Methods
Study Design and Subjects
The reported multicenter, double-masked, randomized,
parallel-group, vehicle-controlled studies had a similar
design and a duration of 5 months. Study 1 was conducted
at eight centers in Japan with subjects who had idiopathic
hypotrichosis of the eyelashes, and study 2 was conducted
at nine centers in Japan with subjects who had chemo-
therapy-induced hypotrichosis of the eyelashes. Three
centers participated in both studies.
The trial period of each study ran from July 2011 to May
2012. Each study was performed in compliance with Jap-
anese Good Clinical Practice, Good Clinical Practice, and
the International Conference on Harmonisation guidelines.
Institutional review board approval was obtained at each
site before initiation of the study, and all the subjects gave
written informed consent.
In both studies, subjects 20 years of age or older were
eligible if they had a Global Eyelash Assessment (GEA)
score of 1 or 2 using the GEA with the associated Photo-
numeric Guide for Japan (GEA-J), a best-corrected visual
acuity score of 20/100 or better for each eye, and an
intraocular pressure (IOP) of 20 mmHg or lower in each
eye. In study 2, the eligible subjects also were required to
report chemotherapy-induced eyelash hypotrichosis after
completion of standard adjuvant chemotherapy for an
early-stage solid tumor. The chemotherapy had to be
completed 4–24 weeks before baseline assessments, and all
side effects related to the chemotherapy had to be grade 1
or less on the Common Terminology Criteria for Adverse
Events (CTCAE, version 4.03). Subjects were excluded
from both studies if they had any uncontrolled systemic
disease, any known ocular disease or abnormality, or a
history of ocular surgery within the previous 3 months.
The subjects were screened for eligibility 3–14 days
before randomization. The eligible subjects were randomly
assigned in a 1:1 ratio to bimatoprost 0.03 % or vehicle by
an interactive voice or by a Web response system on day 1
(baseline). The study medication was dosed once nightly
for 4 months. One drop of study medication was applied to
a sterile, single-use applicator and brushed along the upper
eyelid margins. Separate applicators were used for each
eye. The subjects were advised to remove makeup and
contact lenses before application of the study medication.
Contact lenses could be reinserted after 30 min. The sub-
jects returned to the study center for evaluation at the end
of week 1, then at months 1, 2, 4 (end of treatment), and 5
(posttreatment follow-up assessment).
Efficacy Assessments
The primary efficacy measurement was overall eyelash
prominence as determined by the GEA score using the
GEA-J. The GEA-J scale is identical to the original GEA
scale except that the associated photoguide contains pho-
tographs of Japanese subjects exclusively. Both the GEA
and the GEA-J scales have been validated in previous
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clinical studies [15]. A GEA score of 1 indicates none to
minimal eyelash prominence; a score of 2 indicates mod-
erate eyelash prominence; a score of 3 indicates marked
eyelash prominence; and a score of 4 indicates very marked
eyelash prominence.
The investigators assigned GEA scores based on live, in-
person assessments of overall eyelash prominence across
both eyes. The secondary efficacy end points included
measurements of upper eyelash length (mm), eyelash
thickness (mm2), and eyelash darkness (intensity units)
using a validated digital image analysis (DIA) of superior-
view digital eyelash photographs taken with standardized
equipment and subject positioning at each study visit
(except for week 1). Patient-reported satisfaction with
various attributes of eyelashes also was assessed at each
visit except for week 1 using the 9-item Eyelash Satisfac-
tion Questionnaire (ESQ-9).
The ESQ-9 consists of nine questions and three domains.
Each question is measured on a 5-point Likert-type scale
(i.e., very satisfied, satisfied, neutral, unsatisfied, very
unsatisfied), and each domain consists of three questions.
The three domains are Length, Fullness, and Overall Satis-
faction (LFOS: domain 1, assessing subject satisfaction with
physical attributes of eyelashes); Confidence, Attractive-
ness, and Professionalism (CAP: domain 2, assessing subject
satisfaction with subjective attributes of eyelash health); and
Daily Routine (DR: domain 3, assessing subjects’ percep-
tions of the degree of bother associated with making eye-
lashes presentable). Positive changes in ESQ-9 scores and
domains indicate improvement. The ESQ-9 has been trans-
lated, culturally adapted, and psychometrically validated
with the Japanese population.
Safety
Ophthalmic examinations were performed at screening and
at months 1 and 4. The exams included biomicroscopy and
dilated ophthalmoscopy as well as measurement of best-
corrected visual acuity and IOP. Adverse events (AEs)
were recorded at each visit. Physical examinations and
clinical laboratory testing were performed at screening and
at month 4, and vital signs were obtained at each visit
except for week 1.
Statistical Analyses
The sample size determination in study 1 indicated that a
total enrollment of 126 subjects would provide 90 % statis-
tical power for detecting a 30 % difference in the response
rate between the treatment groups, assuming a 30 %
response in the vehicle control group and a two-sided type 1
error of 0.05. Study 2 was primarily a safety study not
powered for efficacy and enrolled a much smaller cohort.
All efficacy analyses were conducted on the intent-to-
treat (ITT) population, which comprised all of the random-
ized subjects whether they had received study treatment or
not. The primary efficacy end point was prospectively
identified as the clinical response and defined as at least a
one-grade increase in GEA score from baseline at month 4.
Between-group comparisons of the response rate were made
using Pearson’s Chi square test or Fisher’s exact test. The
same method was used to compare the response rates
between the treatment groups at months 1, 2, and 5.
The secondary efficacy end points of change from
baseline to month 4 (the primary time point) in eyelash
length, progressive eyelash thickness, and eyelash darkness
on DIA were calculated as the average of right and left
upper eyelash measurements. Between-group comparisons
were performed using the Wilcoxon rank-sum test. The
ESQ-9 scores for each question and domain (three domains
consisting of three questions each) were analyzed. The
change from baseline on each question was analyzed by
descriptive statistics.
Between-group comparisons for each domain were made
using the Wilcoxon rank-sum test. Missing efficacy data
were imputed using a last-observation-carried-forward
approach up to month 4. No data imputation was made for
missing month 5 data. Differences were considered statisti-
cally significant if the two-sided P value was 0.05 or lower.
Correlation analyses of the change from baseline to month
4 in GEA versus ESQ-9 question 3 (‘‘Overall, how satisfied
are you with your eyelashes?’’), domain 1, and domain 2
were performed to evaluate the direction and strength of the
correlation using the Spearman rank correlation coefficient
(q). Its significance was assessed by the t test.
Safety parameters were evaluated in the safety popula-
tion, which consisted of all the subjects who received at
least one dose of study medication. The AEs were coded
using the Medical Dictionary for Regulatory Activities,
version 15.0. Comparisons of safety parameters were made
using appropriate nonparametric statistical methods (Fish-
er’s exact test, Pearson’s Chi square test, or Wilcoxon rank
sum test) or parametric tests (analysis of variance). No
imputation of missing safety data was made.
Results
Subject Disposition and Demographics
For study 1, a total of 173 subjects were randomized: 88
subjects to bimatoprost and 85 subjects to vehicle. The two
treatment arms were comparable in terms of baseline
characteristics. The overall mean age was 40.8 years, and
89.6 % of the subjects were women. A majority of the
patients (69.9 %) had a baseline GEA score of 2 (Table 1).
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One subject with a baseline GEA score of 3 was random-
ized to the bimatoprost group but did not receive treatment.
This subject was included in the efficacy analyses as part of
the ITT population.
Study 2 randomized 36 subjects to treatment, with 18
subjects in each group. The groups were comparable except
for age. All of the subjects were women, and the majority
(72.2 %) had a GEA score of 1 at baseline (Table 1).
Efficacy: GEA Scores
The proportion of subjects who responded to treatment with
at least a one-grade improvement in GEA score from base-
line to month 4 was significantly greater with bimatoprost
than with vehicle in both study 1 (77.3 vs 17.6 %; P \ 0.001)
and study 2 (88.9 vs 27.8 %; P \ 0.001). In study 1, sig-
nificantly higher response rates with bimatoprost, reflecting
improved eyelash prominence, were evident by month 1 and
maintained at the month 5 posttreatment assessment (Fig. 1).
In addition, a significantly greater proportion of patients in
the bimatoprost group than in the vehicle group experienced
at least a two-grade improvement in GEA score from base-
line, which started at month 2 and continued through the
posttreatment assessment at month 5 (38.1 vs 1.2 % at month
5; P \ 0.001).
Although study 2 was not powered for efficacy, the
statistically significant between-group difference in eyelash
prominence achieved at the month 4 primary time point
was maintained at the month 5 posttreatment assessment
(83.3 vs 27.8 %; P \ 0.001). An example of a subject with
a two-grade improvement at month 4 in study 1 and a one-
grade improvement at month 4 in study 2 is shown in
Fig. 2.
Efficacy: DIA
In both studies, the bimatoprost-treated subjects experienced
significantly greater improvements than the vehicle group
from baseline to month 4 in upper eyelash length, thickness,
and darkness. In study 1, from baseline to month 4, the bi-
matoprost-treated subjects experienced mean improvements
of 1.62 mm (24 %) in upper eyelash length, 0.35 mm2
(44.8 %) in upper eyelash thickness, and -12.02 intensity
units (negative value represents darkening; 8 %) in upper
eyelash darkness (Fig. 3). In contrast, these eyelash param-
eters were essentially unchanged in the vehicle group.
Significant between-group differences were observed for
mean change in eyelash length and darkness, starting at
month 1, and for mean change in eyelash thickness, starting
at month 2. These differences were maintained through
month 5 (all P \ 0.001 except for eyelash darkness at
month 1 [P = 0.012]). In study 2, improvements in these
parameters with bimatoprost compared with vehicle were
statistically significant at month 4 (mean change from
baseline in eyelash length [2.65 vs 0.99 mm; P = 0.003],
eyelash thickness [0.76 vs 0.28 mm2; P = 0.007], and
eyelash darkness [-21.07 vs -4.60 intensity units;
P = 0.040). Examples of improvements in eyelash length,
thickness, and darkness for bimatoprost-treated subjects in
both studies are shown in Fig. 4.
Table 1 Subject demographics and baseline characteristics
Study 1 Study 2
Bimatoprost 0.03 % Vehicle Bimatoprost 0.03 % Vehicle
(n = 88) (n = 85) (n = 18) (n = 18)
n (%) n (%) n (%) n (%)
Mean age: years (range) 40.1 (20–68) 41.4 (20–64) 46.3 (31–61) 54.9 (39–74)
Age distribution
\45 years 58 (65.9) 48 (56.5) 8 (44.4) 3 (16.7)
45–65 years 29 (33.0) 37 (43.5) 10 (55.6) 12 (66.7)
[65 years 1 (1.1) 0 (0) 0 (0) 3 (16.7)
Gender
Males 9 (10.2) 9 (10.6) 0 (0) 0 (0)
Females 79 (89.8) 76 (89.4) 18 (100) 18 (100)
Baseline GEA score
1 (minimal) 30 (34.1) 21 (24.7) 12 (66.7) 14 (77.8)
2 (moderate) 57 (64.8) 64 (75.3) 6 (33.3) 4 (22.2)
3 (marked) 1 (1.1)a 0 (0) 0 (0) 0 (0)
GEA Global Eyelash Assessment
All the subjects were Japanese
a The subject was randomized but did not receive treatment
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Patient-Reported Satisfaction: ESQ-9
In both studies, both treatment groups had similar mean
baseline scores for the nine questions and three domains of
the ESQ-9. In study 1, the bimatoprost group had signifi-
cantly greater improvements from baseline satisfaction
scores in domains 1 (LFOS) and 2 (CAP) (both P B 0.001)
at multiple time points and in the individual questions
comprising these domains than the vehicle group
(P B 0.028). For question 3 in domain 1 (‘‘Overall, how
satisfied are you with your eyelashes?’’), the bimatoprost
group reported significantly greater improvements in sat-
isfaction scores from baseline than the vehicle group at
months 2–5 (P \ 0.001) (Table 2).
No significant between-group differences were observed
for domain 3 (DR) or its individual questions. At month 4,
for the bimatoprost group, the improvements from baseline
in subject satisfaction with eyelashes, as measured by
question 3 (q = 0.381), domain 1 (q = 0.451), and domain
2 (q = 0.409), were positively and significantly correlated
with improvements from baseline in eyelash prominence,
as measured by GEA score (all P \ 0.001). Significant
correlations were not seen in the vehicle group.
In study 2, compared with the vehicle group, the bi-
matoprost group also had significantly greater improvements
from baseline in satisfaction scores at multiple time points in
domains 1 (P B 0.017) and 2 (P = 0.019) and in the indi-
vidual questions comprising these domains (P B 0.05).
Again, in the bimatoprost group, subject satisfaction with
eyelashes, as measured by question 3 (q = 0.641;
P = 0.004), domain 1 (q = 0.516; P = 0.028), and domain
2 (q = 0.538; P = 0.021) in ESQ-9, were significantly
correlated with improvements in eyelash prominence mea-
sured by the GEA score.
Safety Profile: AEs
In study 1, the overall incidence of AEs during the entire
study was similar in the bimatoprost and vehicle groups
(41.4 vs 37.6 %; P = 0.643). The most common AEs in
the bimatoprost group were nasopharyngitis (13.8 %),
conjunctival hyperemia (4.6 %), punctate keratitis (3.4 %),
eye discharge (3.4 %), and skin hyperpigmentation
(3.4 %). None occurred at a significantly higher rate than in
the vehicle group. Each of these common AEs was reported
as mild in severity.
Fig. 1 Percentage of subjects in study 1 with at least a one-grade
improvement in Global Eyelash Assessment score. The study
treatment was applied once nightly for 4 months. The subjects did
not use the study treatment between months 4 and 5. *P = 0.008. 
P \ 0.001 versus vehicle
Fig. 2 Example of subjects from a study 1 and b study 2 who responded to bimatoprost treatment with two- and one-grade improvements,
respectively, in Global Eyelash Assessment (GEA) score at month 4
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Overall, most AEs resolved before the end of the study,
and the vast majority were of mild severity. None of the
AEs reported as moderate or severe was considered by the
investigator to be associated with the study treatment. The
serious AEs in the bimatoprost group included one case
each of appendicitis and pyelonephritis, which were not
considered to be associated with treatment. Three subjects
discontinued the study due to AEs, namely, dry eye and
facial pain (each considered to be treatment related) in the
bimatoprost group and dissociative disorder in the vehicle
group.
In study 2, the overall incidence of AEs in the bimato-
prost group during the entire study was 66.7 % compared
with 72.2 % in the vehicle group (P [ 0.999). The types of
AEs did not differ significantly between the two groups.
Radiation skin injury (related to previous cancer treatment)
and skin hyperpigmentation were the most common AEs in
the bimatoprost group, whereas nasopharyngitis, radiation
skin injury (related to previous cancer treatment), and
insomnia were the most common AEs in the vehicle group.
No other AEs were reported for more than one subject in
either group. No subjects in the bimatoprost group had
serious AEs, and no subjects discontinued the study due to
AEs.
Safety Profile: Ophthalmic Examination
In study 1, ophthalmic examination showed no statistically
or clinically significant differences between the bimato-
prost and vehicle groups in terms of change from baseline
in IOP (mean change from baseline to month 1, -0.79 vs
-0.47 mmHg, P = 0.264; mean change from baseline to
month 4, -0.84 vs -0.23 mmHg, P = 0.085). No subject
had an IOP of 6 mmHg or lower, and no subject had an AE
report of reduced IOP. Visual acuity remained unchanged
(between -2 and ?2 lines) for more than 90 % of the
patients in both groups (P = 0.248) at month 1 and for
more than 85 % at month 4 (P = 0.257). Biomicroscopy
and ophthalmoscopy findings of a one-grade increase from
baseline were observed more frequently in the bimatoprost
group and reflected higher rates of conjunctival hyperemia
(9.2 vs 0 %; P = 0.007). No two-grade increases were
found.
In study 2, the bimatoprost group had a statistically
significantly greater reduction in IOP from baseline than
the vehicle group at the month 1 time point only (-2.21 vs
-0.68 mmHg; P = 0.007). These changes in IOP were not
considered clinically meaningful and, at month 4, the
changes in IOP did not differ significantly between the
treatment groups (-1.50 vs -0.38 mmHg; P = 0.152). As
in study 1, no subject had an IOP of 6 mmHg or lower, and
no subject had an AE report of reduced IOP. Visual acuity
remained unchanged in most of the subjects, except for a
decline of more than two lines in one subject and an
increase of more than two lines in one subject, both in the
bimatoprost group. The biomicroscopy and ophthalmos-
copy findings did not differ between the treatment groups.
No clinically meaningful changes in vital signs, hematol-
ogy, blood chemistry, or urinalysis laboratory data were
observed during either study.
Fig. 3 Mean changes from baseline (± 2 times standard error) in
a upper eyelash length, b thickness, and darkness in study 1. The
study treatment was applied once nightly for 4 months. The subjects
did not use the study treatment between months 4 and 5. A negative
change in eyelash darkness indicates darkening. *P = 0.012.
P \ 0.001 versus vehicle
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Discussion
These randomized clinical trials demonstrated that bimato-
prost 0.03 % applied to upper eyelid margins once nightly
for 4 months was effective and safe for Japanese subjects
with hypotrichosis of the eyelashes, regardless of etiology. A
significantly greater proportion of the bimatoprost-treated
subjects experienced improved eyelash prominence than the
vehicle-treated subjects, as measured by the GEA score. The
bimatoprost-treated subjects also had significantly greater
improvements in upper eyelash length, thickness, and
darkness, as measured by DIA, and greater improvements in
satisfaction with their eyelashes, as measured by ESQ-9,
than the subjects in the vehicle control group.
In study 1, bimatoprost produced significant effects on
eyelash prominence, length, and darkness, starting at
month 1, and on eyelash thickness, starting at month 2. The
bimatoprost-treated subjects in study 1 also experienced
significantly better satisfaction compared with baseline by
month 2 than the vehicle-treated subjects in terms of
length, fullness, and overall satisfaction with their eye-
lashes. Increased improvements in these end points were
seen until the final on-treatment assessment at month 4 (the
primary time point), and the improvements were main-
tained in the posttreatment assessment at month 5. Thus,
bimatoprost produced robust and sustained eyelash
improvements in Japanese subjects with hypotrichosis of
the eyelashes.
Fig. 4 Examples of subjects
who responded to bimatoprost
treatment with an increase in
a upper eyelash length,
b thickness, and c darkness,
including baseline and month 4,
as well as a change from
baseline values (measurements
are rounded to the nearest whole
number). The individual
changes in these subjects were
comparable with the mean
changes observed in the
bimatoprost group in a study 1
and b study 2. IU intensity units
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Study 2 had a smaller sample but exhibited similar tem-
poral trends for efficacy, with significant effects in the bi-
matoprost group compared with the vehicle group at month 4
(the primary time point) on the end points of eyelash prom-
inence, length, thickness, darkness, and overall satisfaction
and at month 2 on the end points of satisfaction with eyelash
length and fullness. These effects were maintained at the
post-treatment assessment at month 5 for most end points.
Although some differences have been noted in the
eyelash morphology of Asians compared with Caucasians
(e.g., number, thickness, and curliness of eyelashes) [19],
the proportion of bimatoprost-treated subjects with at least
a one-grade improvement in GEA score from baseline to
month 4 was comparable between the Japanese subjects in
study 1 and a mostly Caucasian, North American cohort
with idiopathic hypotrichosis of the eyelashes evaluated in
a prior study (77.3 and 78.1 %, respectively) [15]. In both
populations, the improvement in eyelash prominence was
maintained at the post-treatment assessment at month 5.
Moreover, in both populations, the GEA score improve-
ments were significantly correlated with greater patient-
reported satisfaction with eyelashes, as measured with
ESQ-9 in the current study and with the original 23-item
ESQ in the North American study [15].
The safety profile of bimatoprost 0.03 % has been well
established for treatment of open-angle glaucoma and
ocular hypertension [11, 20]. Although the same 0.03 %
drug concentration was used for treatment of hypotrichosis
of the eyelashes, the total dose applied to the eyelid mar-
gins was only approximately 5 % of the dose compared
with an eyedrop [21]. The types of AEs reported in the
current trials were consistent with those of prior studies
investigating mostly Caucasian populations with hypotri-
chosis of the eyelashes [15, 17]. The overall incidence of
AEs and that of each AE type did not differ significantly
between the two treatment groups.
The ophthalmic examinations conducted at months 1
and 4 further confirmed the safety of bimatoprost 0.03 %
for treatment of hypotrichosis of the eyelashes and indi-
cated a good safety profile in Japanese subjects with
hypotrichosis. In both studies, small mean reductions from
baseline IOP were observed in the bimatoprost and vehicle
groups but were not clinically significant.
In study 2, the bimatoprost group had a slightly greater
mean reduction in IOP from baseline at month 1 than the
vehicle group, which was statistically significant. However,
no clinically meaningful change in IOP occurred in any sub-
ject, and no subject had an IOP of 6 mmHg or less at either on-
treatment examination. The normal range for IOPs is report-
edly 7–21 mmHg, and daily fluctuations in IOP can show an
approximate range of 3–7 mmHg [22–25]. Accordingly, the
changes observed in the current studies were well within
normal ranges, consistent with the low exposure to bimato-
prost after topical application to the upper eyelid margins.
Statistically significant between-group differences in IOP
were reported in the North American study from week 1
through week 16. By the week 20 visit, these differences had
resolved [15]. At biomicroscopy and ophthalmoscopy in study
1, a one-grade increase in conjunctival hyperemia observed in
9.2 % of the subjects in the bimatoprost group was reported as
Table 2 Significant differences on the 9-item Eyelash Satisfaction Questionnaire (ESQ-9) by time period between the bimatoprost and vehicle
groups
Item Question Study 1 Study 2
Time period significanta P value Time period significanta P value
1 Length satisfaction Months 2–5 \0.001 Months 2–5 B0.006
2 Fullness/thickness satisfaction Months 2–5 B0.002 Months 2–5 B0.035
3 Overall satisfaction Months 2–5 \0.001 Months 4–5 B0.006
4 Time applying mascara None C0.335 None C0.312
5 Time removing mascara None C0.058 None C0.295
6 Hassle with eyelashes None C0.070 None C0.189
7 Feel confident about looksb Months 2–5 B0.028 Month 4 0.044
8 Feel confident in appearanceb Months 4–5 B0.007 Month 4 0.014
9 Feel attractiveb Months 4–5 B0.004 Months 2–4 B0.050
LFOS Domain 1 (questions 1–3) Months 2–5 B0.001 Months 2–5 B0.017
CAP Domain 2 (questions 7–9) Months 4–5 \0.001 Month 4 0.019
DR Domain 3 (questions 4–6) None C0.317 None C0.123
LFOS length, fullness, and overall satisfaction, CAP confidence, attractiveness, and professionalism, DR daily routine; ESQ-9 nine-item Eyelash
Satisfaction Questionnaire
a Assessments were made at baseline and at months 1, 2, 4, and 5. Time period column shows the months at which significant differences
favoring bimatoprost versus vehicle were observed
b Questions were asked in the context of appearance without the use of mascara
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an AE in 4.6 % of the cases (all cases rated as mild in severity).
The rate of conjunctival hyperemia reported at biomicroscopy
was consistent with that previously reported in a mostly
Caucasian cohort from a prior study [15].
Study 2 enrolled subjects with chemotherapy-induced
hypotrichosis of the eyelashes. These subjects showed greater
improvements in eyelash growth later in the course of bi-
matoprost treatment than the idiopathic cohort in study 1. In
addition, the vehicle group showed greater improvement in
eyelash growth than the vehicle group in the idiopathic pop-
ulation. The observations in the vehicle-treated subjects may
reflect natural hair-growth recovery after chemotherapy.
A limitation of these studies was their relatively short
duration. Nevertheless, both studies showed statistically
significant improvements in efficacy end points as well as a
good safety profile. As noted earlier, the long-term safety
of bimatoprost 0.03 % for glaucoma and ocular hyperten-
sion has been established. Moreover, a good safety profile
has been demonstrated in a 1-year, phase 3 study of bi-
matoprost 0.03 % in subjects with hypotrichosis of the
eyelashes (Clinicaltrials.gov identifier NCT00907426;
results to be reported separately).
In summary, the current studies demonstrated that bi-
matoprost 0.03 % applied topically to the upper eyelid
margins is effective in producing longer, thicker, darker,
and more prominent eyelashes in Japanese subjects who
have hypotrichosis of the eyelashes, with a favorable safety
profile supported by ophthalmic examination.
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Study Sites
Study 1
Study 1 included the following researchers and study sites:
Takafumi Eto, MD (Tokyo Teishin Hospital Chiyoda-ku,
Tokyo, Japan), Kiyonori Harii, MD (Kyorin University
Hospital Mitaka-shi, Tokyo, Japan), Tomoko Hasunuma,
MD (Kitasato Institute Hospital Biomedical Research
Center Minato-Ku, Tokyo, Japan), Shinichi Hirabayashi,
MD (Teikyo University Hospital Itabashi-ku, Tokyo,
Japan), Atsuyuki Igarashi, MD (NTT Medical Center
Shinagawa-Ku, Tokyo, Japan), Yuzo Komuro, MD (Junt-
endo University Urayasu Hospital Urayasu-shi, Tiba
[Chiba], Japan), Ryoji Tsuboi, MD (Tokyo Medical Uni-
versity Hospital Shinjuku-Ku, Tokyo, Japan), and Rie
Yamashita, MD (Shonan Kamakura General Hospital Ka-
makura-shi, Kanagawa, Japan).
Study 2
Study 2 included the following researchers and study sites:
Shinichi Hirabayashi, MD (Teikyo University Hospital It-
abashi-ku, Tokyo, Japan), Yuzo Komuro, MD (Juntendo
University Urayasu Hospital Urayasu-shi, Tiba [Chiba],
Japan), Masujiro Makita, MD (The Cancer Institute Hos-
pital of JFCR Koto-ku, Tokyo, Japan), Masaru Morita, MD
(Fujieda Municipal General Hospital Fujieda, Sizuoka
[Shizuoka], Japan), Masahiro Nakagawa, MD (Shizuoka
Cancer Center Sunto-gun, Sizuoka [Shizuoka], Japan),
Minoru Sakuraba, MD (National Cancer Center Hospital
East Kashiwa-shi, Tokyo, Japan), Yuri Tokunaga, MD
(Hamamatsu Medical Center Hamamatsu, Sizuoka [Shi-
zuoka], Japan), Junji Washizu, MD (JA Shizuoka Kohsei-
ren Enshu Hospital Hamamatsu, Sizuoka [Shizuoka],
Japan, and Rie Yamashita, MD (Shonan Kamakura General
Hospital Kamakura-shi, Kanagawa, Japan).
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